Horizon Pharma

Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Amgen

Amgen on Tuesday said its adjusted fourth-quarter profit rose 15%, driven by a 20% increase in revenue following the biotechnology company's October acquisition of rare disease drugmaker Horizon Therapeutics.

Amgen quarterly profit rises 15% as Horizon deal boosts results

AbbVie

AstraZeneca

Bristol-Myers

Cerevel Therapeutics Holdings Inc

ImmunoGen

Karuna Therapeutics Inc

Mirati Therapeutics

Pfizer

Roche Holding AG

RayzeBio Inc

Seagen

CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.

Cramer names biopharma companies to watch as industry mergers start to pile up

Alnylam Pharmaceuticals

argenx

Blueprint Medicines

Exelixis

Genmab - ADR

Incyte

Sarepta Therapeutics

Alexion Pharma

Celgene

Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions.

5 Biotech Acquisition Targets To Accumulate In 2024

Amgen stock dipped Tuesday after the biotech company reported light sales for its biggest product. But the company boosted its outlook.

Amgen Boosts Outlook Following Horizon Takeover, But Dips On Light Enbrel Sales

We believe that AMGN has overpaid for HZNP's pipeline, since most of its upside potential is attributed to price increases instead of the expanding TAM. The growing debt may also pose headwinds to its profitability and subsequently, dividend growth and balance sheet deleveraging. Then again, it appears that Mr. Market is still convinced about AMGN' profitable growth ahead, as demonstrated by the stock's immense bullish support.

Amgen: Horizon's Pipeline May Be Too Expensive

Amgen said on Friday it had completed the $27.8 billion acquisition of Horizon Therapeutics after it received the go-ahead from the U.S. Federal Trade Commission (FTC) last month on certain conditions.

Amgen completes $27.8 bln Horizon deal

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock?

Horizon Therapeutics (HZNP) Up 10.4% Since Last Earnings Report: Can It Continue?

Some analysts and M&A experts say the settlement agreement doesn't mean that the FTC will stop baring its teeth at other large buyouts in the industry.

The FTC cleared Amgen's $27.8 billion Horizon buyout — here's what it means for other massive pharma deals

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement.

Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement

The Federal Trade Commission will allow Amgen to continue a $27.8 billion purchase of Horizon Therapeutics. The companies anticipate closing the deal in the fourth quarter.

Amgen gets green light from FTC for $27.8B Horizon Therapeutics deal

The Federal Trade Commission said it had agreed to end its legal challenge of the $27.8 billion deal. The pact also dismisses the antitrust claims of six states that joined the FTC in seeking to block the transaction.

Amgen's Deal for Horizon Therapeutics Clears Key Hurdle

Shares of Horizon Therapeutics PLC (NASDAQ: HZNP) are trading materially up today after the FTC allowed Amgen Inc (NASDAQ: AMGN) to move forward with its $27.8 billion acquisition of the biopharmaceutical company.

FTC clears Amgen's $28 billion acquisition of Horizon Therapeutics

The agency previously argued the merger could harm patients who are prescribed Horizon's two fastest-growing drugs.

Amgen's $27.8 Billion Purchase Of Horizon Therapeutics On After FTC Settlement

The Federal Trade Commission makes provision that prohibits “bundling” discounts for some medications.

Amgen, Horizon Therapeutics Stocks Rise After FTC Settlement Over $27.8 Billion Merger

Amgen stock jumped Friday after the company confirmed the FTC officially cleared its $28 billion acquisition of Horizon Therapeutics.

Amgen, Horizon Therapeutics Stocks Jump After FTC Clears Their $28 Billion Marriage

The Federal Trade Commission reached a deal with Amgen Inc. AMGN, -0.60% to approve its $27.8 billion acquisition of Horizon Therapeutics plc, HZNP, -0.07% the agency announced Friday.

FTC settles with Amgen over $27.8 billion takeover of Horizon Therapeutics

The U.S. Federal Trade Commission has allowed drugmaker Amgen Inc to move ahead with its $27.8 billion deal to buy Horizon Therapeutics , CNBC reported on Friday.

U.S. FTC allows Amgen to move forward with $27.8 bln Horizon deal - CNBC

The FTC had filed a lawsuit in May seeking to block the acquisition, arguing that the deal would "stifle competition" in the pharmaceutical industry.

FTC, Amgen strike deal to allow $27.8 billion Horizon Therapeutics acquisition to move forward

Astellas Pharma Inc

Johnson & Johnson

Eli Lilly

Merck

Novo Nordisk

Novartis

Major pharmaceutical companies including Johnson & Johnson NYSE: JNJ, Novartis AG NYSE: NVS, Bristol-Myers Squibb (NYSE: BMY), Merck & Co., Inc. NYSE: MRK, Eli Lilly & Co. NYSE: LLY and Amgen Inc. NASDAQ: AMGN were trading normally following news that their drugs would be subject to next year's Medicare price negotiations.

How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?

Biotech stocks have underperformed the broad market since May, when the Federal Trade Commission moved to block Amgen's proposed acquisition of Horizon Therapeutics. The FTC was aiming to prevent Amgen from stifling potential competition for two of Horizon Therapeutics' drugs.

Is This the Green Light Biotech Stocks Have Been Waiting For?

The FTC's lawsuit against Amgen-Horizon deal is based on unprecedented speculative concerns and would have cleared months ago if it followed well-established precedent.

FTC Attempts To Block Major Biotech Company Merger

The Federal Trade Commission suspends its ongoing lawsuit to block Horizon's (HZNP) acquisition by Amgen until Sep 18, 2023. The company's stock rises 5.8% in response.

Horizon (HZNP) Up as FTC Pauses Acquisition by Amgen Lawsuit

Horizon Therapeutics (HZNP) shares jumped more than 5.5% in early trading Monday after the FTC said it would suspend its challenge to Amgen's (AMGN) acquisition of the drug maker.

Horizon Therapeutics Shares Surge As FTC Postpones Challenge to Merger

Shares of Horizon Therapeutics PLC HZNP, +0.31% gained more than 5% premarket on Monday after the Federal Trade Commission last week paused its legal challenge to Amgen Inc.'s AMGN, -0.09% deal to acquire the biotech company for $27.8 billion. The FTC sued to block the acquisition in May, saying the deal would let Amgen “entrench the monopoly positions” of Horizon treatments for two serious medical conditions.

Horizon Therapeutics shares climb after FTC pauses challenge of deal with Amgen

The U.S. Federal Trade Commission (FTC) has suspended its challenge of Amgen's $27.8 billion purchase of Horizon Therapeutics , allowing the FTC to consider whether the agency should settle the case, a filing late on Friday showed.

US FTC suspends challenge to block Amgen's $27.8 bln deal for Horizon Therapeutics

News for Horizon Pharma Stock (HZNP)